NovoCure (NVCR) News
NASDAQ: NVCRHealth CareMedical/Dental InstrumentsUSD
10.71+0.02 (+0.19%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NVCR news summary
We found 11 recent headlines mentioning NovoCure (NVCR): 0 in the past week and 11 in the past 30 days, most often from Nasdaq, Seeking Alpha, Business Wire. For price context, NVCR is up 0.19% at $10.71. The most recent story, "FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.", was published by Nasdaq on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest NovoCure headlines
- FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.Key PointsMya is an investigational product in the Optune line.Nasdaq
- NovoCure denied FDA approval of Optune Mya for brain metastasesSeeking Alpha
- FDA Cites Uncertainty Over Clinical Benefit In Novocure's Optune Mya Application; Stock Down(RTTNews) - Novocure (NVCR) said Monday that the U.S. Food and Drug Administration (FDA) issued a Not Approvable Letter for its Premarket Approval (PMA) application for Optune Mya, intended to treat…NasdaqNVCR, MOG.B
- NovoCure: 3 Key Takeaways for Long-Term InvestorsKey PointsNovoCure generated record third-quarter net revenue of $193 million.Nasdaq
- Novocure outlines 2026 net revenue of $736M-$743M as it updates adjusted EBITDA to $24M-$34MSeeking Alpha
- NovoCure slips despite quarterly beats, updated guidanceSeeking Alpha
- NovoCure Limited Reports Third Quarter 2026 Financial Results and Raises 2026 GuidanceNovoCure Limited reported its financial results for the third quarter ended September 30, 2026, featuring total net revenues of $193.4 million, representing an increase of 16% compared to the same…NasdaqNVCR, HEI.A
- NovoCure Q3 Loss Decreases(RTTNews) - NovoCure (NVCR) revealed Loss for third quarter of -$10.44 millionNasdaqNVCR, SUN
- NovoCure beats top-line and bottom-line estimates; updates FY26 outlookSeeking Alpha
- Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 GuidanceBAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) today reported financial results for the third quarter that ended September 30, 2026. Novocure is a global oncology company working to…Business Wire
- NovoCure Q3 2026 Earnings PreviewSeeking Alpha